Talk about running fast after securing cash!
On Wednesday, the pharmaceutical company Moderna announced that its chief financial officer, Jorge Gómez, was leaving after a single day at work, but will still be paid his full 12-month salary.
Prior to joining Moderna, Gomez served as Executive Vice President and Chief Financial Officer of Dentsply Sirona Inc. since August 2019.
“The announcement follows the May 10 public disclosure by Mr. Gomez’s former employer, Dentsply Sirona Inc., of an ongoing internal investigation into certain matters, including financial reporting,” Moderna said in a company statement.
The internal probe in question will determine whether the incentives that were used to help sell the dental provider’s products to widespread distributors were “properly accounted for,” according to CNBC.
Gomez’s departure is effective immediately, with the company’s former chief financial officer, David Meline, recently retired, taking over the position during the process of hiring a new candidate.
Related: Moderna shares peak after company says Covid boost boosts antibody levels against Omicron
Gómez was announced as the new CFO of Moderna on April 11, and the position will take effect on May 9.
“It is a privilege for me to join an organization that focuses on developing transformative drugs to address the major public health challenges around the world,” Gomez said at the time. “I look forward to working with the team on this great mission.”
Gomez will still receive his $ 700,000 salary, although he will no longer be eligible for his signature bonus or future bonuses for the one-year period.
John Groetelaars, a board member of Denstsply and a former CEO of Hillrom, currently serves as interim CEO.
The news comes after the April 19 announcement by Dentsply CEO Don Casey had been fired from his position at the company after four years, three weeks before the company announced its earnings less than star Of the first quarter of 2022.
“The first quarter was a challenging quarter and our financial performance and our revised outlook reflect the impact of higher-than-expected macroeconomic headwinds and lower-than-expected performance in the United States,” Groetelaars told shareholders.
Moderna, on the other hand, had an exceptional first quarter, tripling Covid vaccine sales to an estimated $ 5.9 billion in revenue, causing shares to skyrocket more than 7% in pre-trading. at the market on Wednesday.
Related: Modern says his vaccine is 96% effective in teens